Published May 25, 2016

Washington, DC—May 25, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting Issue Panel 18—Precision Medicine: The End of Outcomes Research?—was held this morning in Washington, DC, USA. The moderator for the session was Fadia T. Shaya, PhD, MPH, Professor, Associate Director, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA. Panelists included:

• John Watkins, PharmD, MPH, BCPS, Formulary Manager, Premera Blue Cross, Mountlake Terrace, WA, USA
• Susan Snyder, PhD, MBA, Research Investigator & Health Economist, Center for Health Research, Geisinger Health System, Danville, PA, USA

This Issue Panel explored how precision medicine may impact outcomes research as this new field changes the parameters of what to consider when assessing the value, cost, and cost effectiveness of therapies. Presentations from the ISPOR 21st Annual International meeting can be found here. Interested parties can follow news and developments from the meeting on social media using the hashtag #ISPORDC.

###